The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Apr. 30, 2024

Filed:

Aug. 10, 2018
Applicant:

Good T Cells, Inc., Seoul, KR;

Inventors:

Jung Ho Kim, Seoul, KR;

Beom Seok Kim, Seoul, KR;

Assignee:

GOOD T CELLS, INC., Seoul, KR;

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
C07K 14/435 (2006.01); A61K 35/17 (2015.01); A61K 38/16 (2006.01); A61K 38/17 (2006.01); A61K 39/00 (2006.01); C12N 5/0783 (2010.01); C12N 15/869 (2006.01);
U.S. Cl.
CPC ...
A61K 39/0011 (2013.01); A61K 35/17 (2013.01); A61K 38/162 (2013.01); A61K 38/1774 (2013.01); C12N 5/0636 (2013.01); C12N 15/869 (2013.01); C12N 2501/22 (2013.01); C12N 2501/2302 (2013.01); C12N 2501/2304 (2013.01); C12N 2501/2307 (2013.01); C12N 2501/2312 (2013.01); C12N 2501/2315 (2013.01); C12N 2501/2321 (2013.01); C12N 2501/24 (2013.01); C12N 2501/25 (2013.01); C12N 2502/1107 (2013.01); C12N 2502/1114 (2013.01); C12N 2502/1121 (2013.01); C12N 2502/1157 (2013.01);
Abstract

The present invention relates to a cancer-specific tumor antigen neoepitope represented by any one of SEQ ID NOs: 1 to 214, an antigen-presenting cell loaded with the neoepitope, and a method for activating T cells for cancer treatment using the antigen-presenting cell. An antigen-presenting cell, that is, a dendritic cell, loaded with a cancer-specific tumor antigen epitope provided in the present invention enables rapid and effective induction of differentiation and proliferation of cancer antigen-specific T cells, preferably memory T cells, and the memory T cells thus activated can treat a cancerous or neoplastic condition or prevent recurrence, progression, or metastasis of cancer while avoiding the defense mechanism of cancer cells.


Find Patent Forward Citations

Loading…